BIOMM SA — Investor Relations & Filings

BIOMM SA specializes in the development, manufacturing, and commercialization of complex biopharmaceuticals and biosimilar drug products. Founded as a spin-off from a major insulin producer, the company focuses on advanced treatments for chronic conditions, particularly diabetes. Its portfolio includes human and swine insulins produced via recombinant DNA techniques, alongside specialized delivery systems such as the Biopemm reusable device and Afrezza inhaled insulin. The organization operates a dedicated production facility for the manufacture of high-tech medications and maintains strategic partnerships to broaden its therapeutic reach, including the introduction of semaglutide treatments. The firm emphasizes quality and accessibility in biomedicines, leveraging technical expertise to provide innovative healthcare solutions for patients requiring specialized biological therapies.